Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis

Eun Joo Cho, Jae Hyung Kim, Santosh Sutradhar, Carla Yunis, Mogens Westergaard, CRUCIAL trial investigators, Eun Joo Cho, Jae Hyung Kim, Santosh Sutradhar, Carla Yunis, Mogens Westergaard, CRUCIAL trial investigators

Abstract

Background: Few trials have compared different approaches to cardiovascular disease prevention among Pacific Asian (PA) populations. The Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term-risk (CRUCIAL) trial demonstrated that a proactive multifactorial intervention (PMI) approach (based on single-pill amlodipine/atorvastatin) resulted in a greater reduction in calculated Framingham 10-year coronary heart disease (CHD) risk compared with usual care (UC) among hypertensive patients with additional risk factors. One-third of CRUCIAL patients resided in the PA region. The aim of this subanalysis was to compare two approaches to cardiovascular risk factor management (PMI versus UC) among patients residing in PA and non-PA regions.

Methods: This subanalysis of the CRUCIAL trial compared treatment-related changes in calculated CHD risk among patients residing in PA and non-PA regions. Sensitivity analyses were conducted among men and women and those with and without diabetes.

Results: Overall, 448 patients (31.6%) resided in the PA region and 969 patients (68.4%) resided in non-PA regions. The PMI approach was more effective in reducing calculated CHD risk versus UC in both PA (-37.1% versus -3.5%; P<0.001) and non-PA regions (-31.1% versus -4.2%; P<0.001); region interaction P=0.131. PA patients had slightly greater reductions in total cholesterol compared with non-PA patients. PA patients without diabetes had slightly greater reductions in CHD risk compared with non-PA patients. Treatment effects were similar in men and women and those with diabetes.

Conclusion: The PMI approach was more effective in reducing calculated Framingham 10-year CHD risk compared with UC among men and women with and without diabetes residing in the PA and non-PA region.

Keywords: anticholesteremic agents; antihypertensive agents; cardiovascular disease; clinical trial; hypertension; risk factors.

Figures

Figure 1
Figure 1
Flow of PA and non-PA patients through the CRUCIAL trial. Notes:aTreated patients with baseline and one or more postbaseline efficacy measurements. For one PMI investigator from a non-PA region, four out of 18 patients received UC during the treatment period and were analyzed in the UC arm for the safety population and in the PMI arm for the full analysis set; bhypertension: untreated: SBP ≥160 mmHg and/or DBP ≥100 mmHg; treated: SBP ≥140 mmHg and/or DBP ≥90 mmHg or diabetes: SBP >130 mmHg and/or DBP >80 mmHg. Abbreviations: AE, adverse event; CHD, coronary heart disease; CHF, congestive heart failure; CRUCIAL, Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term-risk; CV, cardiovascular; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; PA, Pacific Asian; PMI, proactive multifactorial intervention; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; TIA, transient ischemic attack; UC, usual care.
Figure 2
Figure 2
Relative percentage change in Framingham 10-year CHD risk, from baseline to week 52 for PA and non-PA patients by treatment arm. Notes:aP<0.001. Patients excluded for missing data: PA PMI, n=6; PA UC, n=2; non-PA PMI, n=6. Abbreviations: CHD, coronary heart disease; CI, confidence interval; LS, least square mean for difference; PA, Pacific Asian; PMI, proactive multifactorial intervention; UC, usual care.
Figure 3
Figure 3
Adjusted mean change from baseline to week 52 in (A) SBP and DBP (mmHg), and (B) TC and LDL-C (%) for PA and non-PA patients. Notes:aP<0.05; bP<0.001; cP=0.051. Patients excluded for missing LDL-C: PA PMI, n=5; PA UC, n=2; non-PA PMI, n=14; non-PA UC, n=16. Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; LS, least square mean for difference; PA, Pacific Asian; PMI, proactive multifactorial intervention; SBP, systolic blood pressure; TC, total cholesterol; UC, usual care.
Figure 4
Figure 4
Study-specific BP and LDL-C goal attainment at week 52 for PA and non-PA patients. Notes:aP=0.002; bP<0.001; cP=0.738; dP=0.004. Patients excluded for missing data: dual goal attainment: PA PMI, n=2; PA UC, n=0; non-PA PMI, n=4; non-PA UC, n=4; LDL-C goal attainment: PA PMI, n=4; PA UC, n=2; non-PA PMI; n=4; non-PA UC, n=4. Abbreviations: BP, blood pressure; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; PA, Pacific Asian; PMI, proactive multifactorial intervention; UC, usual care.
Figure 5
Figure 5
Treatment effect on efficacy measures from baseline to week 52 for men and women in the (A) PA region, and (B) non-PA region. Note:aMean change from baseline to week 52 following treatment with PMI versus UC, adjusted for baseline values. Abbreviations: CHD, coronary heart disease; CI, confidence interval; LS, least square; PA, Pacific Asian; PMI, proactive multifactorial intervention; UC, usual care.
Figure 6
Figure 6
Treatment effect on efficacy measures from baseline to week 52 for PA and non-PA patients with (A) no diabetes, and (B) diabetes. Note:aMean change from baseline to week 52 following treatment with PMI versus UC, adjusted for baseline values. Abbreviations: CHD, coronary heart disease; CI, confidence interval; LS, least square; PA, Pacific Asian; SPAA, single-pill amlodipine/atorvastatin; UC, usual care.

References

    1. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157–2172.
    1. JATOS Study Group Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS) Hypertens Res. 2008;31(12):2115–2127.
    1. Muramatsu T, Matsushita K, Yamashita K, et al. NAGOYA HEART Study Investigators Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension. 2012;59(3):580–586.
    1. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952.
    1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104(23):2855–2864.
    1. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177–1181.
    1. Yagi H, Komukai K, Hashimoto K, et al. Difference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndrome. J Cardiol. 2010;55(3):345–353.
    1. Lawes CM, Rodgers A, Bennett DA, et al. Asia Pacific Cohort Studies Collaboration Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707–716.
    1. Gupta AK, Poulter NR, Dobson J, et al. ASCOT investigators Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens. 2010;23(9):1023–1030.
    1. Zamorano J, Erdine S, Pavia A, et al. CRUCIAL Investigators Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011;27(4):821–833.
    1. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847.
    1. Erdine S, Ro YM, Tse HF, et al. Gemini-AALA Investigators Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study) J Hum Hypertens. 2009;23(3):196–210.
    1. Richard Hobbs FD, Gensini G, John Mancini GB, et al. JEWEL Study Group International open-label program to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil. 2009;16(4):472–480.
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288(23):2981–2997.
    1. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–1158.
    1. Hussein MA, Chapman RH, Benner JS, et al. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. Am J Cardiovasc Drugs. 2010;10(3):193–202.
    1. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006–2010. Med J Aust. 2011;195(3):134–137.
    1. Zamorano J, Erdine S, Lopez AP, et al. CRUCIAL Investigators Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med. 2010;122(2):7–15.
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285(19):2486–2497.
    1. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12 Pt 1):1823–1829.
    1. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410–414.
    1. Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–1163.
    1. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101(3A):22S–32S.
    1. Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol. 1994;73(3):2A–9A.
    1. Masaki Y, Shimada K, Kojima T, et al. Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation. J Cardiol. 2011;57(3):303–310.
    1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–1431.
    1. Radha V, Vimaleswaran KS, Babu HN, et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. Diabetes Care. 2006;29(5):1046–1051.
    1. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–2140.
    1. Kenealy T, Elley CR, Robinson E, et al. An association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New Zealand. Diabet Med. 2008;25(11):1302–1308.
    1. Menotti A, Lanti M, Kromhout D, et al. Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study. Eur J Cardiovasc Prev Rehabil. 2008;15(6):719–725.
    1. Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaad M, CRUCIAL Trial Investigators Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific-Asian patients participating in the CRUCIAL trial. J Korean Med Sci. 2013;28(12):1741–1748.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir